 MaxCyte Inc AIM:MXCT said it has signed a strategic platform license for South Korean chemical company LG Chem to get non-exclusive clinical and commercial rights to use its Flow Electroporation technology and ExPERT platform. The AIM-listed cell-engineering company is entitled to receive platform licensing fees and program-related revenue. 